SKLB1002, a potent inhibitor of VEGF receptor 2 signaling, inhibits endothelial angiogenic function in vitro and ocular angiogenesis in vivo
Sign Up to like & getrecommendations! Published in 2020 at "Molecular Medicine Reports"
DOI: 10.3892/mmr.2020.11056
Abstract: Ocular angiogenesis is a major cause of severe vision loss, which can affect several parts of the eye, including the retina, choroid and cornea. Vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors have demonstrated great… read more here.
Keywords: sklb1002 potent; angiogenesis; sklb1002 administration; ocular angiogenesis ... See more keywords